|
We are a pharmaceutical company currently engaged in the research and
development of innovative pharmaceutical solutions, including an orally
ingestible insulin capsule to be used for the treatment of individuals with
diabetes, and the use of orally ingestible capsules or pills for delivery of
other polypeptides.
Oral insulin: We are seeking to revolutionize the treatment of diabetes through
our proprietary flagship product, an orally ingestible insulin capsule
(ORMD-0801). Having completed Phase IIa clinical trials in patients with both
type 1 and type 2 diabetes, we anticipate the initiation of Phase IIb clinical
trials in approximately 180 patients with type 2 diabetes under an
Investigational New Drug application, or IND, with the U.S. Food and Drug
Administration, or FDA, in the first quarter of calendar year 2015.
|
|